Par Pharmaceutical Companies
One Ram Ridge Road
Spring Valley
New York
10977
United States
Tel: 914-425-7100
Fax: 914-425-7907
Website: http://www.parpharm.com/
110 articles about Par Pharmaceutical Companies
-
A federal judge ordered that information on sales of opioids up to the year 2013 could be released.
-
Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case
5/14/2018
Indivior PLC today announced that its U.S. subsidiary, Indivior Inc., together with Aquestive Therapeutics Inc., entered into a settlement agreement with Par Pharmaceutical, Inc., Par Pharmaceutical Companies Inc., Endo International PLC and IntelGenx Technologies Corp., resolving patent litigation related to SUBOXONE® Sublingual Film.
-
Endo International Completes Acquisition Of Par Pharmaceutical Companies And Provides Financial Guidance
9/28/2015
-
Omeros Corporation Files Infringement Suits Against Par Pharmaceutical Companies
9/3/2015
-
Par Pharmaceutical Companies Begins Shipment of Generic Sodium Edecrin
8/4/2015
-
Par Pharmaceutical Companies Announces Second Quarter 2015 Conference Call
8/3/2015
-
Par Pharmaceutical Companies Receives Favorable Appeals Court Ruling In Generic Exelon Patch Litigation
5/27/2015
-
Par Pharmaceutical Companies Release: Par Specialty Pharmaceuticals Launches Cortisporin-TC Otic Suspension
5/26/2015
-
Par Pharmaceutical Companies Announces First Quarter 2015 Conference Call
5/7/2015
-
Supernus Pharmaceuticals Sues Par Pharmaceutical Companies, Inc. For Infringement Of Trokendi XR® Patents
1/19/2015
-
Par Pharmaceutical Companies, Inc. Announces Quarterly Conference Call
8/6/2014
-
Par Pharmaceutical Companies, Inc. Names Terrance J. Coughlin Chief Operating Officer
4/1/2014
-
Par Pharmaceutical Companies, Inc. Announces Quarterly Conference Call
11/5/2013
-
Par Pharmaceutical Companies, Inc.'s Karen O'Connor Receives 2013 Cardinal Health Supply Chain Excellence Award
10/25/2013
-
Par Pharmaceutical Companies, Inc. Begins Shipment of Generic Kapvay®
10/7/2013
-
Par Pharmaceutical Companies, Inc. Begins Shipment of KHEDEZLA (desvenlafaxine) Extended-Release Tablets, 50 mg and 100 mg
9/23/2013
-
Horizon Pharma, Inc. Announces Settlement of DUEXIS® Patent Litigation With Par Pharmaceutical Companies, Inc.
8/22/2013
-
Par Pharmaceutical Companies, Inc. Receives Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
8/20/2013
-
Par Pharmaceutical Companies, Inc. Announces Quarterly Conference Call
8/5/2013
-
Par Pharmaceutical Companies, Inc. Begins Shipment of Generic Trilipix®
7/18/2013